
Press Release July 27th, 2007

VEMEDIA PHARMA acquires Methapharma (Belgium) and increases capital by 5 million euro

Further growth for Vemedia in Belgium

Methapharma (www.methapharma.com) develops high quality food supplements (nutraceuticals), mainly in the field of arthrosis, arthritis and various cartilage dysfunctions (with Osteoplus as the Belgian market leader), attention deficit (with Attental) en prostate (with Benypro). The company entails a sales and marketing structure in Belgium with teams of reps visiting the doctors and the pharmacists. In total Methapharma employs 25 people. Methapharma also has advanced projects for the distribution of some products on the Chinese market, in collaboration with a local partner.

The 100% acquisition of Methapharma will allow Vemedia to launch, in a fast and efficient way, a selection of its food supplements and OTC-products on the Belgian market. As a consequence, Vemedia is expected to amply exceed its targets in Belgium.

Yvan Vindevogel, CEO of Vemedia comments: "This takeover is a very nice opportunity for us, since we can introduce our products in Belgium earlier than foreseen. By means of its specific market approach, the team of Methapharma has demonstrated its capability to successfully launch different products in the pharmacies with doctors' support."

The (ex-)reference shareholders of Methapharma (amongst which Partners@Venture) will at the same occasion subscribe a capital increase of Vemedia Pharma of 5 million euro.

History of Methapharma

Methapharma was founded in 2003 and is present in the Belgian market since 2005 with glucosamine-products such as Osteoplus, Glucactiv and Chondractiv for a fluid articulation. After some time, Benypro was launched for the prostate and Attental for ADHD (Attention Deficit Hyperactivity Disorder), dyslexia and concentration problems.

Curd Devos, founder of Methapharma explains: "The acquisition of Methapharma by Vemedia offers us the opportunity to optimise our sales structure by adding the Vemedia products to our offerings. All stakeholders are confident about the benefits of this transaction, due to the fact that the synergy between both companies is so clearly present."

Turnover figures

The (non-audited) half-year turnover of the Vemedia Group per June 30th, 2007 amounts to 20.9 million euro which is in line with the budget. Compared to last year's turnover per June 30th, this represents an increase of 30.8%, partly due to the acquisition of ABC Chemicals (October 2006) and Distributie Care BV (December 2006).

On a yearly basis, the acquisition of Methapharma adds revenue of about 5 million euro to the Vemedia Group.

About Vemedia

Vemedia, located in Diemen (the Netherlands) and in Wauthier-Braine (Belgium) is a leading and innovative player in OTC, selfcare and raw materials for the preparation of medicines by pharmacies.

For more information, please contact:

Yvan Vindevogel, CEO: yvanvindevogel@pandora.be

Rob Drenth, COO: rob.drenth@vemedia.nl

Jean-Yves De Vel, CFO: jean-yves.de.vel@vemedia.be

www.vemediapharma.com